JP2004510701A5 - - Google Patents

Download PDF

Info

Publication number
JP2004510701A5
JP2004510701A5 JP2002510040A JP2002510040A JP2004510701A5 JP 2004510701 A5 JP2004510701 A5 JP 2004510701A5 JP 2002510040 A JP2002510040 A JP 2002510040A JP 2002510040 A JP2002510040 A JP 2002510040A JP 2004510701 A5 JP2004510701 A5 JP 2004510701A5
Authority
JP
Japan
Prior art keywords
compound
embedded image
compound according
pyridyl
double bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2002510040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004510701A (ja
JP5101781B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/014721 external-priority patent/WO2001095858A2/en
Publication of JP2004510701A publication Critical patent/JP2004510701A/ja
Publication of JP2004510701A5 publication Critical patent/JP2004510701A5/ja
Application granted granted Critical
Publication of JP5101781B2 publication Critical patent/JP5101781B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2002510040A 2000-05-09 2001-05-08 ピペラジンジオン化合物 Expired - Fee Related JP5101781B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30419100P 2000-05-09 2000-05-09
US60/304,191 2000-05-09
PCT/US2001/014721 WO2001095858A2 (en) 2000-05-09 2001-05-08 Piperazinedione compounds

Publications (3)

Publication Number Publication Date
JP2004510701A JP2004510701A (ja) 2004-04-08
JP2004510701A5 true JP2004510701A5 (enExample) 2008-04-17
JP5101781B2 JP5101781B2 (ja) 2012-12-19

Family

ID=23175471

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002510040A Expired - Fee Related JP5101781B2 (ja) 2000-05-09 2001-05-08 ピペラジンジオン化合物

Country Status (14)

Country Link
US (1) US6635649B2 (enExample)
EP (1) EP1282609B1 (enExample)
JP (1) JP5101781B2 (enExample)
KR (1) KR100852965B1 (enExample)
CN (1) CN100522949C (enExample)
AT (1) ATE417614T1 (enExample)
BR (1) BR0110745A (enExample)
CZ (1) CZ301743B6 (enExample)
DE (1) DE60137037D1 (enExample)
HU (1) HUP0302358A3 (enExample)
NO (1) NO326341B1 (enExample)
RU (1) RU2269520C2 (enExample)
WO (1) WO2001095858A2 (enExample)
ZA (1) ZA200209917B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
PT1311269E (pt) 2000-08-04 2012-05-10 Dmi Biosciences Inc Método de utilização de dicetopiperazinas e composição que contém as mesmas
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) * 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
EP1571970B1 (en) * 2002-10-02 2011-08-17 DMI Biosciences, Inc. Diagnosis and monitoring of diseases
KR20120101164A (ko) 2003-05-15 2012-09-12 디엠아이 바이오사이언시스, 인크 T-세포 매개성 질환의 치료 방법
CA2538352A1 (en) * 2003-09-25 2005-04-07 Dmi Biosciences Inc. Methods and products which utilize n-acyl-l-aspartic acid
WO2005077940A1 (en) * 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
US8129527B2 (en) * 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5856843B2 (ja) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ,インコーポレイテッド ジケトピペラジンを用いた医薬組成物
RU2519948C2 (ru) * 2008-08-22 2014-06-20 Бритиш Коламбиа Кэнсер Эйдженси Бранч Низкомолекулярные ингибиторы n-концевой активации рецептора андрогенов
BRPI1013328A2 (pt) * 2009-04-16 2016-03-29 Telik Inc 4-amino-benzoil-2-(fenilamino) tiofeno-3-carbonitrilas substituídas e 4-a-mino-5benzoil-2-(fenilamino) tiofeno-3-carboxamidas substituídas como inibidores da polimerização de tubulina
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US8710062B2 (en) * 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
EP2766029B1 (en) 2011-10-10 2020-03-25 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
MX2014003856A (es) 2011-10-10 2015-01-16 Ampio Pharmaceuticals Inc Dispositivos medicos implantables con tolerancia inmune incrementada y metodos para hacerlos e implantarlos.
SG11201400283RA (en) 2011-10-28 2014-03-28 Ampio Pharmaceuticals Inc Treatment of rhinitis
AU2014232728B2 (en) 2013-03-15 2019-02-21 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
JP6311097B2 (ja) * 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
EP3183240A4 (en) 2014-08-18 2018-06-27 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
CN104356077B (zh) * 2014-09-11 2016-09-14 中国科学院南海海洋研究所 一类不对称酰基保护的2,5-二酮哌嗪衍生物及其制备方法和应用
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
CN107530341B (zh) 2015-03-06 2021-10-01 大连万春布林医药有限公司 治疗与ras突变相关的癌症的方法
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
DK3334726T3 (da) 2015-07-13 2022-05-16 Beyondspring Pharmaceuticals Inc Plinabulinsammensætninger
AU2017217426B2 (en) 2016-02-08 2022-12-01 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
SG11201810872UA (en) 2016-06-06 2019-01-30 Beyondspring Pharmaceuticals Inc Composition and method for reducing neutropenia
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
CN110381938A (zh) 2017-02-01 2019-10-25 大连万春布林医药有限公司 减少中性粒细胞缺乏症的方法
CA3089226A1 (en) 2018-01-24 2019-08-01 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia via the administration of plinabulin
CN109580801B (zh) * 2018-06-26 2021-09-07 深圳海王医药科技研究院有限公司 一种检测微管蛋白抑制剂及相关杂质的高效液相色谱法
CN112010930B (zh) * 2019-05-28 2022-08-02 首都医科大学 Rgd修饰的五环哌嗪二酮及其制备和应用
EP4319751A4 (en) 2021-04-09 2025-02-26 Beyondspring Pharmaceuticals, Inc. THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
CN117285516A (zh) * 2022-06-16 2023-12-26 大连万众益生大健康有限公司 脱氢苯基阿夕斯汀类化合物、其制备方法及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5973574A (ja) * 1982-10-21 1984-04-25 Grelan Pharmaceut Co Ltd 環状ジペプチド類
US4806538A (en) * 1984-11-02 1989-02-21 Fujisawa Pharmaceutical Co., Ltd. Piperazine compound as PAF-antagonist
GB8609908D0 (en) * 1986-04-23 1986-05-29 Fujisawa Pharmaceutical Co Piperazine compound
DK181687A (da) * 1986-04-23 1987-10-24 Fujisawa Pharmaceutical Co Piperazinderivater og fremgangsmaade til fremstiling deraf
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
JP3795093B2 (ja) * 1994-11-25 2006-07-12 キッセイ薬品工業株式会社 1−ヒドロキシインドール誘導体
JP3131574B2 (ja) * 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤

Similar Documents

Publication Publication Date Title
JP2004510701A5 (enExample)
RU2222534C2 (ru) Замещенные имидазолы, способ их получения, фармацевтическая композиция на их основе, способы лечения цитокин-опосредованных заболеваний
SE9702065D0 (sv) New compound
JP2005526081A5 (ja) 代謝型グルタメート受容体−5の二アリール置換テトラゾールモジュレータ
JP2005508905A5 (enExample)
JP2002543183A5 (enExample)
WO2002016357A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
JP2005502658A5 (enExample)
JP2009534398A5 (enExample)
JP2002521548A5 (enExample)
JP2012510502A5 (enExample)
BR0215202A (pt) Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
WO2002016356A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
DE60239384D1 (de) Formulierungen von borsäure-verbindungen
CA2319275A1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
JP2009533410A5 (enExample)
JP2005505576A5 (enExample)
JP2005507918A5 (enExample)
JP2005536519A5 (enExample)
JP2010511721A5 (enExample)
JP2007510619A5 (enExample)
JP2007519721A5 (enExample)
JP2006526608A5 (enExample)
JP2002155281A5 (enExample)